MedTrace Logo

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

NCT00055419 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 744

Last updated 2010-04-09

No results posted yet for this study

Summary

The purpose of this clinical research study is to learn about the safety of cetuximab in patients with stage IV colorectal cancer, and who may benefit from cetuximab.

Conditions

  • Colorectal Neoplasms

Interventions

BIOLOGICAL

Cetuximab

400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression

Sponsors & Collaborators

Principal Investigators

  • E-mail: ClinicalTrials@ ImClone.com · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2004-07-31
Completion
2004-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00055419 on ClinicalTrials.gov